



PIVAC-19

19th International Conference on Progress in Vaccination Against Cancer

7th–9th June 2019

Hellenic Pasteur Institute, Athens, Greece

Please visit the website <https://pivac19.eu/>



Organized by

- The Cancer Immunology and Immunotherapy Center,
St. Savas Cancer Hospital
- The Hellenic Society of Immuno-Oncology

Scientific Program

Support or Contact

For further details please mail to

- baxevanis@ciic.gr
- info@scep.gr

SILVER SPONSOR



SPONSORS



BRONZE SPONSOR



Advancing Life Sciences - Innovating Health Care™

www.pzafiropoulos.gr

SPONSORS

ANGELICOUSSIS FOUNDATION



«The Antonios and Ioannis Angelicoussis Foundation was established in February 2013. It is a charitable Foundation and it is regulated under private law. The Foundation allocates funds to support non-profit organizations in their sustainable projects -especially child-care units-, educational, cultural and ecclesiastical institutions as well as public hospitals through medical equipment donations».

PAVLIS FOUNDATION Theodoros Pavlis & Kalliopi Prokopaki Public Benefit Organization for Health and Education

Pavlis Foundation is a non-profit organization engaged in public benefit through the areas of health and education, Pavlis Foundation is a grant donated by the surgeon Theodoros Pavlis in 2015. Dr Theodoros Pavlis devoted his whole life for the benefit of cancer patients.



ΙΔΡΥΜΑ ΘΕΟΔΩΡΟΥ & ΚΑΛΛΙΟΠΗΣ ΠΑΥΛΗ



Ησιόδου 12, 106 74, Αθήνα email info@pavlisfoundation.gr www.pavlisfoundation.gr

AEGEAS AMKE



ΑΙΓΕΑΣ
ΑΜΚΕ
ΠΟΛΙΤΙΣΤΙΚΟΥ & ΚΟΙΝΩΦΕΛΟΥΣ
ΕΡΓΟΥ

FRIDAY JUNE 7

09.00-09.30 **Registrations**

New strategies for immune stimulation

09.30-10.00 New strategies to reprogram dysfunctional tumor-infiltrating T cells in paediatric high-risk neuroblastoma

D. Fruci, *Immuno-Oncology Laboratory, Ospedale Pediatrico Bambino, Rome, Italy*

10.00-10.30 Tumor ablation and immune stimulation

G. Adema, *Radiotherapy & Oncolimmunology laboratory, Dept. of Radiation Oncology Radboud UMC, Nijmegen, The Netherlands*

10.30-11.00 The exercise of TAMing the immune system

P.T. Straten, *Center for Cancer Immune Therapy, Department of Hematology, University Hospital Herlev, Denmark*

11.00-11.30 **Coffee break**

Immunomodulation via specific targeting

11.30-12.00 The amino acid transporter xCT in breast cancer (stem) cells

F. Cavallo, *Department of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center, University of Torino, Italy*

12.00-12.30 New generation of personalized cancer vaccines

C. Gouttefangeas, *Group leader at the Institute for Cell Biology, Department of Immunology, Tübingen, Germany*

12.30-13.00 Targeting GARP on human Tregs: a novel approach for the immunotherapy of cancer?

S. Lucas, *de Duve Institute, UCLouvain, Brussels, Belgium*

13.00-15.00 **Lunch**

Immunotherapies during Immune senescence

15.00-15.30 The immune system ages like everything else: what does this mean for cancer immunotherapy?

G. Pawelec, *1. Department of Immunology, Tübingen University, Tübingen, Germany
2. Cancer Solutions Program, Health Sciences North Research Institute, Sudbury, Ontario, Canada*

15.30-16.00 NK cell immunosenescence and NK cell-based immunotherapy in AML patients

R. Solana, *Maimonides Biomedicine Institute of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Cordoba, Spain*

16.00-16.30 Interplay between cellular senescence and cancer

D. Kletsas, *Institute of Biosciences and Applications, NCSR "Demokritos"*

Poster Session I

16.30-17.45 **Oral presentations of selected posters (10 min each)**

SATURDAY JUNE 8

Potentiating Cancer Immunotherapies

- 09.00-09.30 Dissecting T-cell responses in vaccinated, long-term surviving patients
E.M. Inderberg, Department of Cellular Therapy, Oslo University Hospital-The Norwegian Radium Hospital, Oslo, Norway
- 09.30-10.00 Adoptive T-cell therapy in academia – Oslo experiences
G. Kvalheim, MD, PhD, Professor emeritus Gunnar Ikke sensitivt
- 10.00-10.30 Epitope Spreading to Enhance the Effectiveness of TCR Transduced T Cell
M. Nishimura, Research, Department of Surgery, Stritch School of Medicine Loyola University Chicago, USA
- 10.30-11.00 **Coffee break**

Poster Session II

- 11.00-12.30 **Oral presentations of selected posters (10 min each)**
- 12.30 – 14.30 **Lunch**

Immune biomarkers and immunotherapies for hematological diseases

- 14.30-15.00 Next generation sequencing (NGS) – personalized medicine in haematology
A. Madrigal, Royal Free Hospital and UCL Cancer Institute, UCL Country Ambassador for Mexico
- 15.00-15.30 New treatments for leukaemia
A. Madrigal, Royal Free Hospital and UCL Cancer Institute, UCL Country Ambassador for Mexico
- 15.30 – 16.00 Immunotherapeutic targets for the treatment of adult B-cell acute lymphocytic leukaemia
B.A. Guinn, Department of Biomedical Sciences, University of Hull, UK
- 16.00-16.30 Biomarker-guided risk stratification in chronic lymphocytic leukemia
K. Stamatopoulos, Institute of Applied Biosciences, Centre for Research and Technology Hellas, Thessaloniki, GREECE
- 16.30-17.00 Immune checkpoint inhibitors for hematological diseases
G. Vassilopoulos, Haematology Laboratory, Biomedical Research Foundation Academy of Athens (BRFAA), Athens, Greece

SUNDAY JUNE 9

Immune escape and immune suppression

- 09.00-09.30 Cancer immune escape: MHC expression in primary tumors “versus” metastatic lesion
F. Garrido, Departamento de Bioquímica, Biología Molecular III e Inmunología, Facultad de Medicina, Universidad de Granada, Spain
- 09.30-10.00 Role of miRNAs and RNA-binding proteins for the immune escape of tumors
B. Seliger, Institute of Medical Immunology, Martin - Luther - University Halle -Wittenberg, Halle, Germany
- 10.00-10.45 **Coffee break**
- 10.45-11.15 Myeloid cells assist tumor progression by molecular mechanisms either dependent or independent from adaptive immunity
V. Bronte, Immunology Section, Department of Medicine, Verona University Hospital
- 11.15-11.45 How do myeloid-derived suppressor cells (MDSC) survive in the inhospitable tumor microenvironment?
S. Ostrand-Rosenberg, Department of Pathology, Huntsman Cancer Institute, University of Utah, Salt Lake City, USA
- 11.45-12.15 Dynamic interactions within the tumor microenvironment
P. Foukas, 2nd Department of Pathology, National and Kapodistrian University of Athens, Attikon University Hospital, Athens, Greece
- 12.15-12.45 **Special Lecture**
Assessment of Antibody Functional Affinity Using ImmunSpot®
G. Kirchenbaum, Fridolin Franke and Paul V. Lehmann Cellular Technology Ltd, USA
- 12.45-14.30 **Lunch**
- 15.00-20.00 **Excursion**

[illegible]

CTL (Cellular Technology Ltd.) has been pioneering ELISPOT technology for all aspects of immune monitoring. CTL has been the leader in "Elevating ELISPOT to an Exact Science" for over a decade, serving over 3000 clients in academia and industry worldwide and offering unparalleled expertise to the field of immune monitoring.

CTL offers:


- **ImmunoSpot® Analyzers** for fully automated ELISPOT data analysis and streamlined data processing.
- **BioSpot® Analyzers** for high throughput imaging in microplates and automation in data acquisition/analysis of Bioassays.
- **ELISPOT Standardization** including: Standardized ELISPOT kits, standardized protocols and reagents for human PBMC cryopreservation, processing, and testing in high throughput ELISPOT assays; Human PBMC reference sample QC (Quality Control) sets for use as benchmarks for assay performance; Positive and negative controls for immune-assays.

(See our publication for details on our successful efforts in a standardized multi-center T cell immune monitoring study utilizing ELISPOT, Zhang et al, J. Immunotoxicology, 2009, 6:227-34.)
- **PBMC Bank** for human primary cells, providing virtually unlimited quantities of ready-to-use, HLA-typed and immune-characterized human PBMCs from over 100 different donors. These cells have been cryopreserved functionally loss-free, and are ideal for high throughput screening in functional assays such as ELISPOT, ADCC, ICS, etc.
- **Consultation and Hands-on Training** in all aspects of ELISPOT and high-throughput imaging for immune monitoring assays.
- **Contract Research for GLP**, Part 11 compliant, high-throughput ELISPOT testing and other high throughput assays for immune monitoring; we also offer services and logistics for blood sample shipping and cryopreservation using methods which have been proven to retain full functionality of the sample.



Immune Monitoring by ELISPOT

- Cryopreservation of PBMC samples
- Assay development
- Assay qualification & validation
- GLP-compliant testing
- Assay consultation
- PBMC Reference Sample QC Set
- Serum-free test platform
- ELISPOT analyzers & kits




CTL Europe GmbH
Hans-Boeckler-Str. 19-29
53225 Bonn, Germany

Tel +49 (0) 228 85 44 78 - 0
Fax +49 (0) 228 85 44 78 - 22
ctl-europe@immunospot.eu
www.immunospot.eu

IMMUDEX
PRECISION IMMUNE MONITORING

SUPERIOR DETECTION OF ANTIGEN-SPECIFIC T CELLS

Dextramer® detects T cells that Tetramers cannot



IMMUDEX
[+45] 3110 9191
www.immudex.com

ORDERING
[+45] 2913 4224
ordering@immudex.com

CUSTOMER SUPPORT
[+45] 3110 9292
customer@immudex.com



Scientific **I** Cultural Events and Publications **T** +30 2810 222155, +30 210 7240039
F +30 2810 222156, +30 210 7240139 **E** info@scep.gr **www.scep.gr**